Weekly Brief

China Capital Markets Weekly

A weekly briefing on Chinese securities regulation, IPO review, exchange inquiries and enforcement signals.

Current issue ยท 11

Published

A Medical Approval Is Not Yet a Revenue Stream

Reporting period: 28 September to 4 October 2026

Neuracle's brain-computer interface filing separates clinical progress from commercial revenue as semiconductor replies test the assumptions behind growth

Neuracle's invasive brain-computer interface product received medical-device registration in March, but had not generated revenue during the reporting period covered by its prospectus. Its September 29 reply explains the technology alongside losses, R&D and customer accounts. Semiconductor applicants face questions about adoption and profitability, Shenzhen and Beijing listings reach the market, and regional measures address construction advances, board composition and advisory content.

Previous issues

September 2026

Issue 10

21 to 27 September 2026

Airline Growth Meets the Balance Sheet

Loong Airlines' reply brings fleet financing into view, while review decisions and Beijing measures put the week's milestones in context

Issue 08

7 to 13 September 2026

Futures Firms Face a New Rulebook

Futures firms must map activities to licenses and separate transition deadlines; IPO replies examine a different set of operating risks

August 2026

Issue 05

17 to 23 August 2026

A Memory Giant Enters the IPO Queue

Yangtze Memory's STAR Market filing shows the scale of a recovering chip business and the investment still ahead

Issue 02

27 July to 3 August 2026

Governance Beyond the Boardroom

A new governance opinion and investment-banking measures put the work behind formal approvals under scrutiny

July 2026

Issue 01

20 to 24 July 2026

Inside Information and Asset Credit

New ABS guidance tests the underlying cash flow; an insider-trading interpretation moves attention to the start of a deal

Figure